Abstract:Abstract Background Ultrasound-guided peripheral nerve block is difficult to accurately identify the diffusion location of injected local anesthetics. Moreover, current available local anesthetics are limited in duration, which is inadequate for the treatment of prolonged pain. We designed a drug delivery system by using adhesive polylactic-co-glycolic acid (PLGA) microbubbles loaded with ropivacaine to accurately identify and deliver the local anesthetics to the desired targeted site for prolonged analgesic time in rat pain models. Methods The adhesive PLGA-ropivacaine microbubbles (APRMs) were fabricated by coating polydopamine on the PLGA microbubbles with ropivacaine embedded in the shell. Ropivacaine release and ultrasonographic experiments of APRMs were conducted in vitro. Then, incision surgery and SNI-induced neuropathic pain were conducted for adult male rats to verify the ropivacaine release of APRMs in vivo. Ultrasound imaging was performed to confirm the ultrasonic visualization of APRMs. The in vivo fluorescence imaging experiment was conducted for the adhesion property of APRMs. Finally, systemic toxicity and tissue reaction were histologically evaluated. Results In vivo, these microbubbles were able to accurately identify and release local anesthetics to targeted sites for prolonged analgesia. Results showed that APRMs not only presented a continuous release of ropivacaine for at least 16 days, but also exhibited strong dispersed echo spots in agarose gel. In animal model studies, APRMs alleviated mechanical allodynia and thermal hyperalgesia in neuropathic and postoperative pain, which lasted at least 7 days. More importantly, the APRMs performed a lower agent spread area and longer analgesic time than PRMs and ropivacaine groups in thermal analgesic test. Additionally, histological systemic toxicity and tissue reactions evaluated that APRMs did not display any detectable systemic toxicity or adverse tissue reactions. Conclusions APRMs served as an excellent nerve blocker in this delivery system to achieve accurate, sustainable, and safe analgesic efficacy for pain management.

Analgesic drug delivery via recombinant tissue plasminogen activator and microRNA-183-triggered opening of the blood-nerve barrier

Microrna 218 Modulates Pkc/Akt Pathway To Protect Lidocaine-Induced Neurotoxicity In Ganglia In Vitro

Pulsed Radiofrequency to the Dorsal Root Ganglion or the Sciatic Nerve Reduces Neuropathic Pain Behavior, Decreases Peripheral Pro-Inflammatory Cytokines and Spinal Β-Catenin in Chronic Constriction Injury Rats

MicroRNA-21-5p functions via RECK/MMP9 as a proalgesic regulator of the blood nerve barrier in nerve injury

Axotomy-Induced Up-Regulation of Tumor Necrosis Factor-Alpha in the Dorsal Root Ganglia

MiR-340 Regulates Fibrinolysis and Axon Regrowth Following Sciatic Nerve Injury

Intrathecal Lentivirus-Mediated RNA Interference Targeting Nerve Growth Factor Attenuates Myocardial Ischaemia-Reperfusion Injury in Rat.

Exogenous tissue plasminogen activator enhances peripheral nerve regeneration and functional recovery after injury in mice.

P2X7 receptor‐mediated release of microglial prostanoids and miRNAs correlates with reversal of neuropathic hypersensitivity in rats

Intrathecal Administration of Cyclic AMP Response Element-Binding Protein-Antisense Oligonucleotide Attenuates Neuropathic Pain after Peripheral Nerve Injury and Decreases the Expression of N-methyl-D-aspartic Receptors in Mice.

MCRT, a Multifunctional Ligand of Opioid and Neuropeptide FF Receptors, Attenuates Neuropathic Pain in Spared Nerve Injury Model

NLRP3 Inhibition Reduces rt-PA Induced Endothelial Dysfunction under Ischemic Conditions

Perineural resiniferatoxin prevents the development of hyperalgesia produced by loose ligation of the sciatic nerve in rats

Targeted Polymersomes Enable Enhanced Delivery to Peripheral Nerves Post-Injury

Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory Responses

IKBKB siRNA-Encapsulated Poly (Lactic- co-Glycolic Acid) Nanoparticles Diminish Neuropathic Pain by Inhibiting Microglial Activation

Upregulation of miR-133a-3p in the Sciatic Nerve Contributes to Neuropathic Pain Development

Recovery of blood-nerve barrier is delayed in tissue plasminogen activator gene knockout mice after sciatic nerve crush

Amygdala-Targeted Relief of Neuropathic Pain: Efficacy of Repetitive Transcranial Magnetic Stimulation in NLRP3 Pathway Suppression

Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model

Mussel-inspired Injectable Microbubbles Delivery System for Drug Ultrasound Contrast and Long-lasting Analgesic Effect in Peripheral Nerve Block